Shares of HealthEquity (HQY) surged 5.09% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2026 results and upward revision of full-year guidance. The health savings account (HSA) provider demonstrated robust financial performance, surpassing analyst expectations and showcasing significant year-over-year growth.

HealthEquity reported a 9% year-over-year increase in revenue, reaching $325.83 million for the quarter, beating the analyst estimate of $320.82 million. The company's bottom line saw an even more substantial improvement, with net income soaring 67% to $59.9 million. Adjusted earnings per share came in at $1.08, significantly outperforming the Street estimate of 92 cents.

The strong quarterly performance prompted HealthEquity to raise its full-year fiscal 2026 guidance across all major metrics. This optimistic outlook, coupled with the company's solid execution in expanding its HSA business and improving operational efficiency, has garnered positive attention from Wall Street. Several analysts, including those from JPMorgan, BTIG, and Bank of America Securities, have maintained their bullish stance on the stock, with some raising their price targets in response to the results. The pre-market surge reflects investors' confidence in HealthEquity's growth trajectory and its positioning in the expanding HSA market.